Compass Therapeutics (CMPX) Share-based Compensation (2019 - 2026)

Compass Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $5.1 million in Q1 2026.

• Quarterly Share-based Compensation rose 722.45% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 million (up 303.13% YoY) and the FY2025 annual result came in at $13.7 million, down 24.31% from the prior year.
• Share-based Compensation eased to $5.1 million in Q1 2026 per CMPX's latest filing, from $7.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $19.5 million in Q2 2025 and troughed at -$4.4 million in Q4 2023.
• A 5-year average of $4.0 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2026: Share-based Compensation sank 525.46% in 2023, then soared 722.45% in 2026.
• Over 5 years, Share-based Compensation stood at $1.0 million in 2022, then tumbled by 525.46% to -$4.4 million in 2023, then surged by 151.32% to $2.2 million in 2024, then surged by 237.49% to $7.6 million in 2025, then slumped by 32.83% to $5.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $5.1 million, $7.6 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.